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Aryl hydrocarbon receptor (AhR) activation during pregnancy, and in adult nulliparous 
mice, delays the subsequent development of DMBA-induced mammary tumors. 
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Abstract: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), the prototypic ligand for the aryl 
hydrocarbon receptor (AhR), promotes tumor formation in some model systems. However with 
regard to breast cancer, epidemiological and animal studies are inconclusive as to whether 
exposure increases tumor incidence or may instead be protective. We have previously reported 
that mice exposed to TCDD during pregnancy have impaired differentiation of mammary tissue, 
including decreased branching and poor development of lobulo-alveolar structures. Because 
normal pregnancy-induced mammary differentiation may protect against subsequent neoplastic 
transformation, we hypothesized that TCDD-treated mice would be more susceptible to chemical 
carcinogenesis after parturition. To test this, mice were treated with TCDD or vehicle during 
pregnancy. Four weeks later, DMBA (7,12-dimethylbenz[a]anthracene) was administered to 
induce mammary tumor formation. Contrary to our hypothesis, TCDD-exposed parous mice 
showed a four-week delay in tumor formation relative to controls, and had a lower tumor 
incidence throughout the 27-week time course. The same results were obtained in nulliparous 
mice given TCDD and DMBA on the same schedule. We next addressed whether the delayed 
tumor incidence was a reflection of decreased tumor initiation, by testing the formation of 
DMBA-DNA adducts and preneoplastic lesions, induction of cytochrome P450s, and cell 
proliferation. None of these markers of tumor initiation differed between vehicle- and TCDD-
treated animals. The expression of CXCL12 and CXCR4 was also measured to address their 
possible role in tumorigenesis.  Taken together, our results suggest that AhR activation by TCDD 
slows the promotion of preneoplastic lesions to overt mammary tumors.  
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Introduction: 
The aryl hydrocarbon receptor (AhR) is an orphan nuclear receptor that belongs to the PAS 
(per-arnt-sim) family of transcriptional regulators.1 For many years this receptor has been studied 
primarily because of its role in the toxic effects of dioxin-like compounds, which are ubiquitous 
and long-lived contaminants in the environment.2 Recently however, interest in further 
understanding this receptor has been bolstered by numerous reports indicating that the AhR plays 
a role in normal development, carcinogenesis and cell cycle regulation, and likely has 
endogenous ligands with important biological functions.3-6 Because of such discoveries, the 
development of non-toxic analogs of known AhR ligands for therapeutic use has begun to be 
explored.7-9 
TCDD (2,3,7,8-tetrachlordibenzo-p-dioxin) is the best-characterized AhR ligand, and it 
affects many organ systems and deregulates numerous cellular pathways.2, 10 TCDD is also 
classified as a class 1 carcinogen by the International Agency for Research on Cancer,11 and is 
established as a promoter for certain tumors including liver and skin.12, 13  For breast cancer 
however, the relationship between exposure to AhR ligands and cancer risk is unclear. There are 
conflicting reports as to whether exposure to AhR ligands is associated with increased incidence 
of mammary neoplasias, or if it may in fact protect against breast cancer. Investigations of 
human populations exposed to dioxin-like chemicals report mixed findings of increased and 
decreased association with breast cancer risk, while others fail to show any correlation at all. 14-17 
Collectively, studies conducted in rat models indicate that susceptibility to mammary tumors 
likely correlates with the age of the animal, and by extension the differentiation state of the 
mammary gland, at the time of TCDD exposure. For example, studies conducted by Safe and 
colleagues using mature adult rats demonstrated that TCDD, and other AhR agonists, can 
actually cause regression of existing chemical-induced tumors.18-20 Similarly, Kociba et al21 
found reduced incidence of spontaneous mammary tumors in a long-term feeding with TCDD, 
despite increases in incidence of tumors at other locations. In contrast to the experiments wherein 
TCDD is administered to adult rats, other studies addressing developmental exposure to TCDD 
have demonstrated increased sensitivity to mammary tumorigenesis. Specifically, Lamartiniere 
and colleagues have shown that prenatal exposure to TCDD, which alters normal development of 
the mammary gland, increased the incidence of 7,12-dimethylbenz[a]anthracene (DMBA)-
induced mammary tumors later in life.22, 23  Finally, during the neonatal and weaning period, 
administration of AhR agonists may also influence subsequent development of mammary 
tumors, with somewhat conflicting results depending on the timing of exposure and the mixture 
administered.24, 25  
 One emerging paradigm to reconcile these seemingly conflicting results is that the ultimate 
susceptibility of mammary tissue to carcinogenic insult is dependent upon the status of the tissue 
at the time of AhR activation. More specifically, one way by which AhR ligands such as TCDD 
influence mammary tumorigenesis is by interfering with normal timing of development and 
differentiation of the gland, such as during fetal development.26, 27 In support of this idea, 
Lamartiniere and colleagues have shown that developmental exposure to TCDD significantly 
increases the relative number of terminal end buds (TEB) compared to developed type II lobules 
at postnatal day 50.22  Because TEB are very susceptible to carcinogenic transformation, this 
hypothesis fits well with the observed increase in sensitivity to DMBA-induced tumorigenesis in 
rats exposed developmentally to TCDD.22, 23 
The differentiation of mammary tissue that occurs during pregnancy represents another 
critical window during which TCDD exposure causes profound suppression of normal 
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development. Specifically, we have shown that mice treated with TCDD starting at the very 
beginning of pregnancy have observable defects in branching as early as day 6, and severely 
stunted development of lobuloalveolar structures with concomitant suppression of milk 
production by the end of pregnancy.28, 29 Given that AhR activation impairs pregnancy-
associated mammary gland development, we hypothesized that these defects would influence 
susceptibility to tumorigenesis postpartum. The rationale for this idea is that pregnancy-induced 
changes in the mammary gland may provide protection against breast cancer later in life.30-32 
Although the specific alterations responsible for this protection are not fully understood, this 
protective effect is thought to result from permanent changes in the differentiation status or fate 
of the mammary cells that are induced by pregnancy.30-32  
The goal of the studies presented here was to determine whether mice treated with TCDD 
during pregnancy demonstrate increased susceptibility to a mammary carcinogen administered 
after parturition. In other words, we considered that our discovery that TCDD suppresses 
pregnancy-induced mammary differentiation provides at least one mechanistic explanation for 
the correlation between AhR-mediated perturbation of normal mammary differentiation and 
altered incidence of breast cancer. Interestingly, our results showed that AhR activation delayed 
tumorigenesis regardless of pregnancy status and despite the suppression of pregnancy-induced 
glandular development.  Further exploration into the mechanism of the delay suggested that prior 
AhR activation does not reduce carcinogen-induced DNA damage and the initiation phase of 
carcinogenesis. Instead, we postulate that the fate of the mammary epithelial cells is persistently 
altered by AhR activation to slow the proliferation and promotion of initiated cells.   
 
 
Materials and Methods: 
 
Animals: Female CB6F1 mice were obtained from NCI Charles River. Both parental strains 
(BALB/c and C57Bl/6) express the high affinity AhRb allele that confers sensitivity to TCDD.33 
Animals were given food and water ad libitum, and were maintained on a 12:12 hour light cycle. 
For experiments conducted in pregnant animals, female mice (age 6-7 weeks) were housed with 
males and checked daily for presence of vaginal plugs. Day 0 of pregnancy was designated as the 
day the vaginal plug was found. All treatment was in accordance with protocols approved by the 
Washington State University Institutional Care and Use Committee.   
 
Chemicals and animal exposures: TCDD was dissolved in anisole and diluted in peanut oil to a 
concentration for dosing at 10 µl per gram body weight. Mice were administered TCDD in three 
weekly doses of 10 µg/kg (on day 0 and 7) and 5 µg/kg (on day 14). Preliminary dose-response 
studies indicated that 10 µg/kg TCDD on days 0 and 7 was necessary for substantial suppression 
of pregnancy-induced gland differentiation in this strain. The dose given on day 14 was 
decreased in order to speed clearance of TCDD from the body after parturition. Mice were 
treated every 7 days in order to maintain a relatively constant body burden of TCDD throughout 
pregnancy;the half-life of TCDD in mice is 11 days.34 Nulliparous mice were treated under the 
same TCDD paradigm as pregnant mice to serve as controls for the effect of pregnancy. 
Nulliparous mice were also used for some of the mechanistic studies, due to the fact that 
pretreatment with TCDD was determined to affect tumor formation equivalently in parous and 
nulliparous mice, and because it is logistically easier to maintain and treat nulliparous mice for 
tissue collection. Vehicle control for the TCDD treatments consisted of peanut oil containing an 
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equivalent concentration of anisole.  DMBA (7,12-dimethylbenz[a]anthracene, Sigma, St. Louis, 
MO) was dissolved in sesame oil under gentle heat to a final concentration of 5 mg/ml (for 
administering 1 mg in 200 µl).35 The solution was stored at 4°C and kept protected from light at 
all times. Sesame oil was given as the vehicle control for the DMBA treatments. Both TCDD and 
DMBA, and their vehicle controls, were administered by gavage. 
 
Tumor study: 
Experimental design overview: A graphic of the experimental design is shown in Figure 1. 
Female mice CB6F1 mice (age 6-7 weeks) were housed with males and checked daily for 
presence of vaginal plugs. Pregnant mice (n=32 per treatment group) were treated with 10 µg/kg 
of TCDD, or peanut oil vehicle, on days 0 and 7 of pregnancy, and with 5 µg/kg on day 14. Pups 
were removed at birth in order to eliminate lactation as a potential confounding factor (dams 
treated with these doses of TCDD do not lactate and their pups would not survive 28). The dams 
received no further treatment for 4 weeks after the final TCDD treatment, which is equivalent to 
3 weeks after parturition, to decrease the residual body burden of TCDD and to permit the glands 
to regress. Following the no exposure period, mice were treated with 1 mg DMBA per week for 
six weeks.36 Nulliparous age-matched animals were treated with the same doses of TCDD (n=20) 
or its vehicle (n=22) and with DMBA on the same schedule as the parous mice. Control groups 
of vehicle- and TCDD-treated parous mice (n=20 per treatment group) were not given DMBA, 
but instead were administered sesame oil vehicle. These non-DMBA control animals never 
developed palpable tumors.  
Tumor assessment: Mammary tumor formation was monitored by physical palpation twice 
weekly, beginning five weeks after the final administration of DMBA. The location of the 
tumors was recorded. Once a tumor had enough 3-dimensional structure to measure, the size was 
monitored weekly using a vernier caliper. Two perpendicular diameters, termed length (L) and 
width (W), were determined, with length defined as the larger of the two measurements. Volume 
was calculated using the formula 4/3 x pi x (L/2) x (W/2)2.37 The multiplicity of tumors was 
determined as follows: (the total number tumors per group) / (number of mice with tumors in that 
group). 
Termination: Mice were euthanized by carbon dioxide overdose when a tumor length reached 
25 mm, or if at any time the animal appeared uncomfortable or moribund. The tumor study was 
terminated at 27 weeks after the final DMBA administration. At that time, greater than 90% of 
the mice in each DMBA group had either developed palpable tumors or had died of other causes. 
DMBA is a multisite carcinogen, and some of the mice developed other malignancies (often 
thymoma, also ovarian, lung, etc) that contributed to morbidity and mortality. 
Evaluation of preneoplastic lesions: Preneoplastic lesions, including hyperplastic alveolar 
nodules (HAN), ductal carcinoma in situ (DCIS), and ductal hyperplasia (DH) in the mammary 
whole mounts were quantified.38, 39 Additionally, non-preneoplastic lesions in the gland were 
quantified, including cystic nodules (CN), fine duct hyperplasias (FDH), dense nodules (DN), 
and mammary tumors (MT). Cystic nodules were defined as focal areas of dilated alveoli. Dense 
nodules were small highly stained areas comprised of epithelial and stromal cells surrounded by 
dense connective tissue and with a very low mitotic index. Mammary tumors were microscopic 
foci of epithelial cells that proliferated into the surrounding stroma. Samples of all types of 
lesions were verified by histological sections. Lesions were identified in a subset of mice (n=11-
19 per group) that were sacrificed within a consistent window of time relative to DMBA 
administration (≥22 weeks after final DMBA treatment). 
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Whole mounts: Mammary whole mounts were prepared as described previously.28 Briefly, the 4th 
and 5th mammary glands were mounted onto a glass slide under weight, and fixed in Carnoy's 
fixative.  Fixed glands were transferred to 70% ethanol, rehydrated, and stained with carmine 
alum.  Glands were then dehydrated, cleared with xylenes, and mounted using Permount (Fisher 
Scientific, Pittsburgh, PA). Whole mounts were examined and given a development score based 
on a four-point scale. The development scores considered epithelial branching, development of 
lobulo-alveolar units, and the size of the structures (1=poor development, 4=excellent 
development). Photographs were taken at 3.1x using a Jenoptik ProgRes C12plus digital camera 
attached to a Wild Dissecting Microscope. 
 
Western Blotting: The levels of cytochrome P450s (Cyps) 1a1 and 1b1 and of AhR were 
assessed in protein extracts from mammary gland and/or liver. Tissues were homogenized in 
RIPA buffer and protease inhibitors using a Tissue Tearor (Biospec Products, Inc). The proteins 
in the supernatant were quantified and boiled in SDS-PAGE sample buffer. Thirty µg of protein 
was separated on 8%  acrylamide gels, and transferred to PVDF membranes. Primary antibodies 
for Cyp1a1, Cyp1b1, and Actin were purchased from Santa Cruz Biotech (Santa Cruz, CA), and 
the primary antibody for AhR was purchased from BIOMOL International (now Enzo Life 
Sciences, Plymouth Meeting, PA). Secondary antibodies included IRDye™ 700DX Conjugated 
anti-goat IgG (Li-Cor, Lincoln, Nebraska) and HRP-conjugated anti-rabbit antibody 
(DakoCytomation, Glostrup, Denmark). Bands were visualized using the Li-Cor Odyssey ™ 
Infrared Imaging System (for IRDye reagents), or by exposure to x-ray film following incubation 
with chemiluminescent ECL reagents (for HRP-conjugated reagents). The intensity of the bands 
was evaluated using the Li-Cor software or from scans of x-ray films using Quantity One 
(BioRad, Hercules, CA), as appropriate for each secondary antibody conjugate. 
 
DMBA-DNA adduct assay: Genomic DNA from homogenized mammary glands was isolated by 
a standard phenol-chloroform extraction method.40 DNA adducts were determined for each DNA 
sample using the nuclease P1 enrichment version of the 32P-postlabeling method as described 
previously.41, 42 Briefly DNA samples (4 µg) were digested with micrococcal nuclease (120 mU) 
and calf spleen phosphodiesterase (40 mU), enriched and labeled as reported. Chromatographic 
conditions for thin-layer chromatography (TLC) on polyethyleneimine-cellulose (PEI-cellulose) 
(10 cm × 20 cm;Macherey-Nagel, Düren, Germany) were: D1, 1.0 M sodium phosphate, pH 6; 
D3, 3.5 M lithium-formate, 8.5 M urea, pH 3.5; D4, 0.8 M lithium chloride, 0.5 M Tris-HCl, 8.5 
M urea, pH 8. After chromatography, TLC sheets were scanned using a Packard Instant Imager 
(Dowers Grove, IL, USA) and DNA adduct levels (RAL, relative adduct labeling) were 
calculated from adduct cpm, the specific activity of [γ-32P]ATP and the amount of DNA (pmol of 
DNA-P) used. Results were expressed as DNA adducts/108 nucleotides.  
 
Cell Proliferation Analysis: The incorporation of BrdU (bromodeoxyuridine) was used to 
measure the proliferation status of mammary epithelial cells. An intraperitoneal injection of 
BrdU (50 mg/kg, Sigma-Aldrich, St. Louis, MO) was given one day prior to sacrifice. 
Abdominal-inguinal mammary glands were formalin-fixed, paraffin-embedded, and sliced for 
immunohistochemical (IHC) analysis of BrdU incorporation. A BrdU IHC System Kit 
(Calbiochem, San Diego, CA) was used to stain the BrdU positive cells according to the 
manufacturer’s instructions. To count the BrdU positive epithelial cells in each tissue slice, 10 
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images were generated for one slice of each gland using QCapture Pro51 software (Qimaging, 
Surrey, BC, Canada) and a Nikon microscope at magnification 400x.  
 
Real-time PCR: Quantitative real-time PCR (qRT-PCR) analyses were performed to measure 
mRNA levels of the chemokine CXCL12 and its receptor CXCR4 in mammary tissue and 
tumors. Actin was used as an endogenous control. Total RNA was extracted from mammary 
glands homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA). One µg of total RNA was 
reverse-transcribed to single strand cDNA using High-Capacity cDNA Reverse Transcription kit 
(Applied Biosystems Inc. [ABI], Foster City, CA). qRT-PCR reactions were performed using the 
ABI Prism 7000 Sequence Detection System. TaqMan reagents and gene expression assays were 
from ABI. A 25 µl reaction mixture containing 5 µl of cDNA template, 12.5 µl TaqMan 
Universal PCR master mix and 1.25 µl primer probe mixture was amplified using the following 
thermal cycler parameters: denaturation at 95°C for 10 min, then 40 cycles of the amplification 
step (denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min). Raw CT (cycle 
threshold) values were obtained from the ABI7000 software, and used to compare the mRNA 
levels between the vehicle- and TCDD-treated groups. The fold-change between the treatment 
groups was calculated by first determining the ∆CT value (∆CT = CT(target RNA) -
CT(endogenous control)) for each sample. The unlogged ∆CT (= 2-∆CT) was then determined for 
each vehicle-treated animal, then normalized to 1 using the average unlogged ∆CT of all samples 
in that group. The relative fold-change for each TCDD-treated animal was calculated by 
comparison to the average of the vehicle-treated group. The unlogged ∆CT (= 2-∆CT) for each 
animal was used for statistical analysis. 
 
Statistics: Tumor incidence was analyzed by Fisher’s exact test and by ANOVA, using Tukey’s 
test for pairwise comparisons. Other comparisons were made using Students t test. A p-value of 
≤ 0.05 was considered significant. Statistical analyses were performed using Prism (GraphPad 
Software, La Jolla, CA) or Minitab (Minitab Inc., State College, PA).  
 
 
 
Results: 
 
Part 1: Effect of AhR activation on mammary gland differentiation and tumor incidence. 
AhR activation suppresses pregnancy-induced differentiation of mammary glands in CB6F1 
mice. 
Previous studies conducted in C57Bl/6 mice have demonstrated that AhR activation during 
pregnancy suppresses normal branching and lobuloalveolar development in the mammary gland. 
The central hypothesis for the current study was that this suppressed differentiation would result 
in increased susceptibility to mammary tumorigenesis postpartum. Because C57Bl/6 mice are 
less susceptible to chemical-induced carcinogenesis than the Balb/c strain,43 CB6F1 mice (Balb/c 
X C57Bl/6) were used for these tumorigenesis studies. Therefore, the first objective was to 
demonstrate the suppressive effect of TCDD on pregnancy-induced gland differentiation in this 
particular mouse strain.  
 Impregnated mice were treated with 10 µg/kg TCDD on days 0 and 7 of pregnancy, and with 
5 µg/kg on day 14. Mammary whole mounts were made from glands taken on day 17 of 
pregnancy. As shown in Figure 2, AhR activation decreased the normal branching that occurs 
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during pregnancy and resulted in poor development of lobulo-alveolar structures. Development 
scores quantifying the amount of differentiation in glands showed that the suppression caused by 
TCDD treatment was statistically significant (Figure 2C). The effects presented in Figure 2 are 
similar to those reported previously in TCDD-treated C57Bl/6 mice.28, 29 
 
Prior AhR activation decreases susceptibility to DMBA-induced mammary tumorigenesis.  
Evidence in both humans and rodents suggests that pregnancy may cause changes in 
mammary cells that reduce the probability of developing mammary tumors later in life.32, 44-46 
Because TCDD suppresses differentiation of the mammary gland when given to mice during 
pregnancy, we tested whether these mice would be more susceptible to DMBA-induced tumor 
formation later on. To accomplish this, mice were treated with TCDD or vehicle control during 
pregnancy, pups were removed at birth and the dams remained untreated for 3 weeks post-
partum. DMBA was administered once a week for 6 weeks, and palpable tumors were evaluated 
over time. Interestingly, we found that mice treated with TCDD during pregnancy had a 
decreased tumor incidence relative to the vehicle-treated parous animals at all times examined 
(Figure 3A). Specifically, the number of tumor-positive mice at a given time point was decreased 
by an average of 17% in the TCDD-treated group compared to the vehicle-treated group (range 
9-22% lower, depending on the week). The difference between the two groups was highly 
significant (p < 0.0001). Furthermore, the average week of tumor onset (relative to the final 
DMBA treatment) was delayed by nearly four weeks in the TCDD-treated animals (Figure 3E, 
parous mice, p < 0.05). 
The same beneficial effect of prior AhR activation was observed in nulliparous mice treated 
with DMBA (Figure 3B, p < 0.0001). Specifically, the number of tumor-positive mice at a given 
time point was decreased by an average of 18% in the TCDD-treated group compared to the 
vehicle-treated group (range 7-30% lower, depending on the week). The average time of tumor 
onset was also delayed by over three weeks in mice with prior TCDD exposure (Figure 3E, 
nulliparous mice, p = 0.065). 
 
Parity status alone does not alter tumor incidence. 
A separate but important consideration in these studies was the effect of parity status on 
tumor incidence. Pregnancy is hypothesized to protect against tumor development in rats and 
humans, and therefore nulliparous mice were included in the study to serve as controls for the 
parous animals. However, our results showed that a single pregnancy did not protect against 
tumor development, because tumor formation in nulliparous mice was essentially the same as for 
the parous animals. In other words, there were no statistically significant differences in the tumor 
incidence curves between the vehicle-treated parous mice and the vehicle-treated nulliparous 
animals (Figure 3C; p=0.30). Neither did we observe differences between the TCDD-treated 
parous animals and the TCDD-treated nulliparous mice (Figure 3D; p=0.18).  
 
Tumor size and multiplicity are not significantly altered by prior AhR activation. 
We next determined whether growth of the mammary tumors was affected by prior exposure 
to TCDD. It is important to emphasize that we intentionally addressed the growth rate of tumors 
once they had formed. That is, given that there was an overall delay in tumor formation in the 
TCDD-treated mice, the number and size of tumors in TCDD groups were smaller at a given 
week following DMBA exposure.  Therefore, the growth of each tumor was monitored relative 
to the time of initial onset in that animal. 
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Tumor growth was assessed in three ways. First, we calculated the number of days between 
the time each tumor was first detectable by palpation and when it grew large enough to measure 
with calipers. As shown in Figure 3F, prior TCDD exposure caused a statistically significant 
retardation of tumor growth in the nulliparous mice, but not in parous animals. This result is 
suggestive that prior AhR activation slows tumor growth in addition to the timing of tumor onset, 
and that the protective effect is more pronounced in nulliparous animals. However, for the other 
two methods used to evaluate tumor growth we did not observe a difference based on parity or 
TCDD pretreatment. Specifically, when we determined the volume of each tumor on days 7, 14, 
and 21 after the tumor was first large enough to measure, neither prior exposure to TCDD nor 
parity status affected tumor volume at any time point (data not shown). Likewise, the number of 
tumors that formed in each affected animal was not significantly affected by either TCDD 
treatment or parity (tumor multiplicity: Vehicle-Parous = 1.13, TCDD-Parous = 1.37; Vehicle-
Nulliparous = 1.53, TCDD-Nulliparous = 1.45). 
 
 
Part 2: Effect of AhR activation on tumor initiation. 
Chemical carcinogenesis is considered a multi-step process, consisting of initiation, promotion, 
and progression. In the next series of experiments we addressed the hypothesis that prior 
activation of the AhR specifically alters tumor initiation. Initiation parameters examined 
included P450 induction and DNA damage, carcinogen-susceptible proliferating epithelial cells, 
and formation of preneoplastic lesions. 
 
Persistent AhR activation and Cytochrome P450 induction is unlikely at the time of carcinogen 
administration. 
In the experimental design for the tumor study, administration of the carcinogen (DMBA) 
began four weeks after the final treatment with TCDD. The intent of this delay was in part to 
allow time for the TCDD to be cleared and reduce/eliminate the influence of persistent AhR 
activation at the time the tumors were forming. In other words, our intent was to test whether the 
fate of the mammary epithelial cells was changed by prior AhR activation, not to examine the 
effect of concurrent AhR activation on a carcinogenic insult.  However, it remained possible that 
the AhR was still activated four weeks after TCDD treatment, such that persistent induction of 
P450 enzymes could alter the biotransformation of the carcinogen DMBA.  
To address AhR activation status at the time of DMBA administration, the levels of Cyp1a1 
and Cyp1b1 proteins were measured four weeks after the final treatment with TCDD, using a 
cohort of mice separate from the tumor study.  For comparison, the induction of these enzymes 
was also determined three days after the final treatment with TCDD. As expected, Cyp1a1 and 
Cyp1b1 were highly induced in both the mammary gland and liver three days following TCDD 
treatment (Figure 4, left panels). However, in the mammary gland these enzymes were 
completely absent by four weeks after treatment (Figure 4A, right panels). Similar results were 
observed in the liver samples, where Cyp induction was markedly reduced, although still 
detectable and statistically different (p < 0.05), by four weeks post-exposure (Figure 4B, right 
panels). These results strongly support the conclusion that persistent AhR activation, particularly 
in the mammary gland itself, is not responsible for the delay in tumor formation. Furthermore, 
the absence of persistent induction of Cyp enzymes suggests that differences in DMBA 
metabolism are unlikely to account for the delay in tumor formation in the mice pretreated with 
TCDD. 
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Given that TCDD treatment is known to cause rapid degradation of the AhR, which could 
likewise affect the response to DMBA, we also examined the level of AhR protein in the 
mammary glands. Consistent with other reports showing diminished AhR expression in cultured 
cell lines, mammary gland, and other tissues,47-50 we found that AhR levels in the mammary 
gland were significantly lower in TCDD-treated mice when assessed 3 days following treatment 
(Supplementary Figure 1). However AhR levels had recovered within the 4 weeks following the 
final TCDD exposure, and there was no persistent difference in receptor levels between the 
treatment groups at the time DMBA was administered.  
 
 
Influence of TCDD on DMBA-DNA adduct levels 
The initiation phase of chemical carcinogenesis begins with damage to the DNA bases. For 
DMBA, metabolites of the chemical form covalent adducts with DNA that can result in DNA 
mismatch and mutation. To directly test whether prior exposure to TCDD alters the formation 
of these lesions, the amount of DMBA-DNA adducts in the mammary glands was investigated 
by 32P-postlabeling analysis. Representative TLC autoradiographs are shown in Figure 5A. The 
adduct pattern observed after oral administration of DMBA (in the presence or absence of 
TCDD) was similar to that found in mouse skin epidermis after topical application.41 It 
consisted of three major adduct spots, which have been shown to represent DMBA-DNA 
adducts formed by bay-region diol epoxides. No DNA adducts were detected in non-DMBA 
control tissues (data not shown). Total DMBA-DNA adduct levels are illustrated in Figure 5B. 
The level of DMBA-DNA adducts increased in response to the number of DMBA treatments 
the animals received, at around 120 and 350 adducts per 108 nucleotides after one and six 
DMBA doses, respectively. However, prior treatment with TCDD did not change the damage 
to the DNA bases (adducts) caused by DMBA. 
 
Proliferation status of mammary epithelial cells at the time of carcinogen exposure. 
 Mammary epithelial cells that are rapidly proliferating may be more susceptible to damage 
by carcinogens, as evidenced by the correlation between mammary tumor incidence and number 
of proliferating cells in the ducts and end buds.22, 31, 45 To test whether prior exposure to TCDD 
reduced the number of proliferating mammary epithelial cells (i.e., those cells possibly most 
susceptible to DNA damage and mutation), BrdU incorporation was examined by 
immunohistochemistry. Mice that had been treated with three weekly doses of vehicle or TCDD 
were injected with a single dose of BrdU 4 weeks after their final treatment. Proliferating cells 
were quantified by counting the number of cells that stained positively for BrdU (Figure 5C). 
The analysis revealed that prior AhR activation did not diminish the number of proliferating 
mammary epithelial cells 4 weeks later (Figure 5D, left columns, “Baseline”), which was the 
time at which the DMBA was administered.  
In separate groups of pretreated animals, a single dose of DMBA was given (Figure 5D, right 
columns, “DMBA”). The goal was to determine if prior AhR activation dampens the 
proliferative response of the mammary epithelial cells resulting from DNA damage. As expected, 
the DMBA treatment itself increased the number of proliferating cells relative to cells from mice 
not given DMBA (Baseline); however there was no effect of prior treatment with TCDD. Taken 
together, these results show that TCDD does not cause persistent suppression in the baseline 
proliferative status of mammary epithelial cells, nor in their initial proliferative response to DNA 
damage.  
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Evaluation of preneoplastic and other microscopic lesions. 
 In addition to macrosopic measurable tumors, DMBA and other carcinogens induce the 
formation of other lesions in the mammary gland, some of which are preneoplasias. To ascertain 
whether prior activation of the AhR influences formation of these microscopic lesions, six types 
of lesions were evaluated in mammary glands from mice in the tumor study. Specifically, these 
lesions included two preneoplastic lesions (hyperplastic alveolar nodules and ductal carcinoma in 
situ/ductal hyperplasia) and four others (cystic nodules, fine duct hyperplasias, dense nodules, 
and mammary tumors). Table I shows the average number of each type of lesion found in each 
animal, the percentage of animals in each group with that lesion, and the multiplicity of each 
lesion type.  Overall, there were no consistent differences in the incidence of these lesions 
between the different treatment groups. These results further support the conclusion that tumor 
initiation is not diminished by prior activation of the AhR, because the number of preneoplastic 
and other lesions in the TCDD-treated mice is similar, and in some cases even slightly higher, 
than in vehicle control mice. 
 
Part 3: Effect of TCDD treatment on CXCL12 and CXCR4 in vivo. 
In a recent publication by Hsu et al,51 the authors reported that TCDD treatment of MCF-7 
cells reduced the expression of the chemokine CXCL12 and its receptor CXCR4. This discovery 
may be significant because these two factors have been implicated in breast cancer metastasis, 
and a reduction in their expression was postulated to play a role in the protective role of AhR 
activation in breast cancer. 
To address the potential for changes in CXCL12 and CXCR4 to contribute to the delay in 
tumor growth in the DMBA model, as well as to further characterize the expression of these 
factors in vivo, we determined their mRNA levels using qRT-PCR. Mammary glands were 
collected from mice treated with three weekly doses of vehicle or TCDD. In one group of mice, 
CXCL12 and CXCR4 levels were examined three days after the final treatment with vehicle or 
TCDD. At this time point, both CXCL12 and CXCR4 levels were significantly increased in the 
TCDD-treated animals, by 2-fold and 3.5-fold respectively (Figure 6A). However, when we 
examined message levels of CXCL12 and CXCR4 four weeks later, the TCDD-mediated 
increase did not persist (Figure 6B). Moreover, the levels of the mRNAs in the DMBA-induced 
mammary tumors themselves were not found to differ between the vehicle- and TCDD-treated 
groups (Figure 6C). There was suggestive evidence for a decrease in CXCR4 expression in 
tumors from TCDD-treated mice, however the difference was not technically statistically 
significant.  
 
 
 
 
Discussion: 
 
 Breast cancer is among the leading killers of women world-wide52 and there is a clear need 
for developing novel therapeutic options and preventative measures. One strategy that has been 
proposed for treating breast cancer is the use of selective AhR modulators (SAhRMs).  The use 
of such compounds is based on the fact that AhR is expressed in mammary cells and that AhR 
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activation antagonizes estrogen receptor (ER) signaling and inhibits tumor growth.8, 18-21 
Additionally, new evidence suggests that SAhRMs may also be effective in treating estrogen 
receptor-negative tumors.9 The goal of the current studies was to test whether AhR activation 
during pregnancy affects susceptibility to a genotoxic mammary carcinogen administered weeks 
later. Interestingly, we found that prior exposure to TCDD delayed tumor onset and reduced 
tumor incidence in adult mice. Furthermore, this beneficial effect of AhR activation occurred 
regardless of whether TCDD was given during pregnancy or to nulliparous animals. These 
interesting results provide additional support and insight for a protective role of AhR activation 
in mammary tumorigenesis. 
In our studies, TCDD was administered 4 weeks before the animals were given DMBA and ≥ 
14 weeks had elapsed by the time the first tumors formed. Therefore it was important to consider 
whether the beneficial effects resulted from persistent levels of TCDD in the body or from 
persistent changes in the fate of the mammary cells caused by previous AhR activation. To 
address this, we examined the level of Cyp1a1 and Cyp1b1, which are sensitive and commonly-
used biomarkers of AhR activation. Our results showed that Cyp expression in the mammary 
gland itself had returned to background levels within the 4 weeks following TCDD treatment. 
Given that only minute amounts of TCDD are needed to induce Cyp1a1 and Cyp1b1,53 our 
results do not support the idea that residual TCDD is directly affecting tumor growth in our 
studies. Further support for this interpretation is provided by knowledge that the half-life of 
TCDD in AhRb mice is 7-10 days,54, 55 so the majority of the TCDD was cleared prior to the 
growth phase of the tumors. Therefore we speculate that the protection afforded by prior AhR 
activation results from a change in the fate of the mammary epithelial cells that causes resistance 
to neoplastic transformation.  
While numerous studies have shown that AhR activation is protective against mammary 
carcinogenesis, the precise mechanism of the protection remains unclear. We began our 
investigation into the mechanism of delayed tumor formation by examining the impact of prior 
AhR activation on the initiation stage of carcinogenesis. Specifically we examined whether mice 
treated with TCDD four weeks prior had (i) persistent induction of metabolic enzymes that 
biotransform DMBA, (ii) decreased numbers of DMBA-DNA adducts, or (iii) diminished 
proliferation status of the mammary epithelial cells at the time of carcinogen administration. We 
also compared (iv) the levels of preneoplastic lesions in the mammary glands of the TCDD- and 
vehicle-exposed animals. Each of these four markers relevant to tumor initiation was equivalent 
in mice from both treatment groups, suggesting that DNA damage and tumor initiation were not 
diminished by prior exposure to the AhR agonist. Taken together, these data strongly suggest 
that prior AhR activation is not altering tumor initiation in this model.  
Instead, we speculate that prior AhR activation is interfering with the second stage of 
chemical carcinogenesis, tumor promotion. This is supported by the findings that the level of 
DMBA-DNA adducts and the incidence of preneoplastic lesions was the same in the TCDD- and 
vehicle-treated mice, yet the ultimate development of palpable tumors was suppressed in TCDD-
exposed animals. TCDD is known to influence tumor promotion in other models, and is in fact 
established as a tumor promoter in skin and liver.4, 56, 57 While these opposite effects in different 
tissues may at first appear to be irreconcilable, it is plausible that they reflect cell- and context-
dependent differences in AhR-mediated effects on cell cycle regulation and apoptosis. For 
example, AhR activation is known to influence cell proliferation and apoptosis in many cell lines 
and tissues; however, the precise nature of the effects (increased versus decreased) vary 
depending on the cell as well as by the treatment conditions.12, 13, 58-61 Thus in summary, because 
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the TCDD-exposed mice in our studies had a longer latency period and decreased mammary 
tumor incidence at any given timepoint, it is more logical that TCDD decreases promotion in this 
model. Furthermore AhR-mediated suppression, or even reversal, of tumor promotion is a 
reasonable explanation for the regression of pre-existing mammary tumors reported previously. 
18-20
  
While many studies in rodents show that AhR activation reduces mammary tumor 
growth, the complex relationship between mammary tumorigenesis, constitutive expression and 
function of AhR in tumors, and activation of the receptor by exogenous ligands is not fully 
elucidated. Studies conducted by Dave Sherr and colleagues demonstrate that AhR is 
overexpressed in mammary glands and tumors from DMBA-treated animals,62, 63 and the 
receptor is also detected in many breast cancer cell lines and human tumors.64-67 Endogenous 
expression and activation of AhR in mammary tumors likely influences cell cycle regulation, and 
may promote tumor growth by stimulating cell proliferation and inhibiting apoptosis.68, 69 On the 
other hand, AhR activation with TCDD and SAhRMS typically inhibits breast cancer cell growth 
in rodent models. This may be explained, at least for ER+ cancer cells, by cross-talk between 
AhR and ER. For example, exogenous AhR activation perturbs the expression or function of 
numerous genes that influence proliferation of breast cancer cells, including c-fos , TGF-β, TGF-
α, and receptors for progesterone, prolactin and estrogen (reviewed in 70). Mechanisms for this 
antiestrogenic activity may include competition between activated AhR and ER for shared 
cofactors, binding of AhR to inhibitory response elements in promoter regions of ER-inducible 
genes, or AhR-enhanced proteosomal degradation of the ER.70-72 In future studies we will 
examine the status of AhR, hormone receptors, oncogenes, and other modulators that influence 
growth of cancer cells. This will require collecting lesions and tumors from vehicle and TCDD 
pretreated mice systematically throughout the course of tumor growth, and is part of our ongoing 
investigation into the underlying molecular pathways that are disrupted by prior TCDD treatment 
to delay tumor onset.  
A separate issue raised by the current studies is unrelated to the effect of AhR activation; 
specifically the observation that pregnancy alone did not protect against tumor formation. In 
other words, the tumor incidence curve for the vehicle-treated parous mice was not different 
from that of the vehicle-treated nulliparous animals.  Nor was there a difference in tumor 
formation between the TCDD-parous and TCDD-nulliparous mice.  This finding was somewhat 
surprising, since pregnancy is hypothesized to protect against breast cancer in humans and has 
been demonstrated in rat models.30-32 However, we are aware of only one report that has directly 
addressed the protective effect of pregnancy in an analogous chemical carcinogen-treated mouse 
model. Specifically, Medina and Smith46 found that pregnancy plus lactation reduced the 
incidence of DMBA-induced tumors by approximately 3-fold and lengthened the latency period 
by 10 weeks. Although our current study did not show evidence of protection provided by 
pregnancy, differences in the experimental designs may explain the different outcomes. 
Specifically, in the Medina and Smith study the dams nursed their pups for one week, whereas in 
the current study we removed the pups at birth. Given that lactation is thought to further reduce 
the incidence of mammary tumors above pregnancy alone,73 it is highly probable that this 
explains the differing outcomes in the two studies. 
Our results also provide insight into understanding the mechanism of protection against 
breast cancer afforded by pregnancy. Specifically, we found that mammary cell differentiation 
alone, at least differentiation that contributes to branching and lobuloalveolar development, is not 
likely a causal factor in parity-induced protection against tumor formation. In this model, AhR 
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activation during pregnancy dramatically suppressed branching, lobuloalveolar development, and 
milk production (Figure 2 and 28, 29). However, suppressed glandular development did not 
correlate with increased risk of developing mammary tumors, which suggests that additional 
factors other than differentiation must play a role.  
The chemokine CXCL12 and its receptor CXCR4 are known to function in leukocyte 
migration to inflammatory sites.74 With regard to turmorigenesis, CXCR4 is often over-
expressed in human cancers, and CXCL12 may also play a role in survival, proliferation or 
angiogenesis in the primary tumor.75, 76 Additionally they are believed to play a role in directing 
the migration of cancer cells to secondary metastatic sites.77 Hsu et al51 recently reported that 
TCDD treatment reduced the expression of these factors in MCF-7 cells, and postulated that this 
may contribute to the protective effect of AhR activation in breast cancer. A subsequent report 
by Hall et al described similar suppression of CXCR4 by TCDD in additional ER+ and ER-  
breast cancer cell lines.67 In our studies, TCDD treatment caused a transient increase in the 
expression of both molecules in the mammary gland. The cause of this increase in the absence of 
antigen challenge is unclear, although it could reflect an enhanced inflammatory response that is 
commonly observed in TCDD-treated animals.78-80 Regardless, this increase was transient and 
did not persist at the time of carcinogen administration. There was suggestive evidence that 
CXCR4 expression was diminished in tumors from the TCDD-treated mice, which would be 
consistent with observations by Hsu et al and Hall et al in the cultured tumor cells. However the 
decrease was not technically statistically significant. Taken together our results do not provide 
strong support for a link between delayed tumor formation and changes in CXCL12 or CXCR4, 
although the potential for these molecules to influence continued tumor growth or metastasis 
warrants further exploration. 
As discussed previously, Lamartiniere and colleagues have demonstrated that developmental 
exposure to TCDD alters gland development and also increases susceptibility to mammary 
tumorigenesis.22, 23 Thus it is reasonable that the differentiation state of cells in the mammary 
gland at the time of AhR activation will influence susceptibility to neoplastic transformation. Our 
original intention was to test whether the AhR-mediated suppression of normal pregnancy-
induced mammary differentiation would likewise increase susceptibility to tumor development.  
However, our results did not support this hypothesis for glandular differentiation caused by 
pregnancy. We did not find that altered glandular development caused by TCDD influenced the 
development of DMBA-induced tumors; tumor development was delayed by TCDD treatment 
regardless of whether the animal was pregnant or not at the time of exposure.  
In summary, our results show that AhR activation causes a persistent change in mammary 
cells that delays tumor formation, and add to the growing number of studies that have 
demonstrated that AhR activation reduces mammary tumor incidence or causes regression of 
existing tumors. In combination with other findings such as overexpression of AhR in mammary 
tumors,62, 63, 68 effects of AhR activation on cell cycle regulation and invasiveness of breast 
cancer cells,67, 81 and the discovery that a metabolite of tamoxifen activates AhR,82 this report 
underscores the importance of understanding the role of the receptor in breast cancer. We 
hypothesize that the beneficial effect observed in our studies occurs via inhibiting tumor 
promotion, specifically by slowing the growth of preneoplastic lesions and initial tumors. This is 
promising because it provides an opportunity for biologic intervention in situations where 
initiation has already occurred, and provides tantalizing evidence to support continued 
exploration into the use of SAhRMs in breast cancer treatment and prevention. 
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Figure Legends: 
 
Figure 1: Tumor study design and animal treatment. Six groups of CB6F1 mice (age 6-7 
weeks at the start of the experiment) were included in this study. Pregnant mice were treated 
with vehicle (n=32) or TCDD (n=32) at 3 time points during pregnancy, followed by 6 weekly 
doses of DMBA beginning 4 weeks after the final TCDD treatment (equal to 3 weeks after 
parturition). Nulliparous age-matched mice were treated with vehicle (n=22) or TCDD (n=20) 
and DMBA on the same schedule as the pregnant mice. Finally, vehicle- and TCDD-treated 
control groups that did not receive DMBA were also included. For these “no DMBA” controls, 
pregnant mice were treated with vehicle (n=20) or TCDD (n=20) during pregnancy, then given 
sesame oil (the vehicle control for DMBA) beginning three weeks after parturition. No tumors 
developed in the mice that did not receive DMBA. See Methods for additional details about the 
TCDD and DMBA treatments. 
 
Figure 2: Mammary gland differentiation that occurs during pregnancy is disrupted by 
AhR activation. Impregnated CB6F1 mice were treated with vehicle (A; n=7) or TCDD (B; 
n=5) at three times during pregnancy (10 µg/kg on day 0 and day 7, and 5 µg/kg on day 14). 
Whole mounts of the abdominal mammary glands were made on day 17 of pregnancy, fixed, and 
stained with carmine alum. (C) Glands were given scores that considered epithelial branching, 
development of lobulo-alveolar units, and the size of the structures. Bars indicate the mean score 
for each treatment group (± SEM). * p ≤ 0.05. Representative photos of glands from vehicle-
treated (A, developmental score = 4) and TCDD-treated (B, developmental score 1.5) mice were 
taken at 3.1x 
 
Figure 3: Prior treatment with TCDD delays tumor formation in DMBA-treated parous 
and nulliparous mice. The development of mammary tumors was monitored by physical 
palpation beginning 5 weeks after the final treatment with DMBA and continued for 27 weeks. 
(A) Incidence of mammary tumors in DMBA-treated parous mice (triangles) that had been 
treated with vehicle (open triangles, n=32) or TCDD (filled triangles, n=32) during pregnancy. 
The difference between the two groups was highly significant (p < 0.0001 as analyzed by 
ANOVA using a Tukey’s test for pairwise comparisons). No tumors formed in parous control 
mice that were not given DMBA (vehicle group = open diamonds, n=20; TCDD group = X 
symbol, n=20). (B) Tumor incidence in DMBA-treated nulliparous mice (circles) that had been 
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treated with vehicle (open circles, n=22) or TCDD (filled circles, n=20) and DMBA on the same 
schedule as the parous mice. The difference between the two groups was highly significant (p < 
0.0001). (C and D) The same experimental groups shown in panels A and B were re-graphed to 
demonstrate the observed lack of effect of pregnancy on subsequent tumor incidence. The 
incidence of mammary tumors in DMBA-treated parous (triangles) and nulliparous mice 
(circles) is shown both for mice pretreated with vehicle control (C) or with TCDD (D). Statistical 
comparisons showed no difference between the parous and nulliparous groups (p = 0.30 for C; 
and  p = 0.18 for D). (E) Average time of tumor onset (± SEM) relative to the final DMBA 
treatment. (F) Growth rate was assessed by determining the number of days between the time 
each tumor was first detected by palpation until it grew large enough to physically measure with 
vernier calipers. * p ≤ 0.05;  # p = 0.065. 
 
Figure 4: Cytochrome P450 induction is transient and returns to baseline by four weeks 
following TCDD treatment. Cyp1a1 (56kDa) and Cyp1b1 (57kDa) were assessed in protein 
extracts from (A) mammary gland and (B) liver using Western blotting. Mice were treated with 
three weekly doses of vehicle or TCDD, as described in the Methods. Tissues were collected at 
two time points, including three days after, and four weeks after the final vehicle or TCDD 
treatment. The positive (+) control for Cyp1a1 is liver extract from a TCDD-treated mouse, and 
for Cyp1b1 is protein from cultured mammary epithelial cells (SCp2 cells) treated with 10-9M 
TCDD for 5 days. Actin (43kDa) was used as a loading control. Bar graphs in (B) illustrate the 
magnitude of the difference in Cyp1a1 induction present at 3 days vs 4 weeks following TCDD 
exposure. Similar results were obtained for Cyp1b1. Tissues from pregnant mice were used in 
the three day timepoint, and nulliparous mice were the source of tissues taken at 4 weeks. Parity 
status did not substantially affect baseline Cyp expression in the liver of vehicle-treated animals 
when proteins were compared on the same blots (≤14% difference, not shown). * p ≤ 0.05. 
 
Figure 5:  Prior activation of the AhR does not change the level of DMBA-DNA adducts in 
the gland or the proliferative status of mammary epithelial cells. Nulliparous mice were 
treated with three weekly doses of vehicle or TCDD, as described in the Methods. (A, B) Four 
weeks after the final vehicle or TCDD treatment, the carcinogen DMBA was administered to 
initiate tumor formation. Mice were sacrificed 24 hours after receiving either one dose of 
DMBA, or after receiving six weekly doses of DMBA (n=6 mice per treatment group at each 
time point). The number of DNA adducts in DNA extracted from the mammary glands was 
determined by 32P-postlabeling. (A) The patterns of DMBA-DNA adducts are shown in 
representative TLC autoradiographs. Arrows indicate the three major adduct spots, which 
represent adducts formed by DMBA bay-region diol epoxides.  (B) Levels of adducts (RAL = 
relative adduct labeling) in the vehicle- and TCDD-pretreated mice that were subsequently given 
one or six doses of DMBA. (C, D) Four weeks after the final vehicle or TCDD treatment, the 
proliferating mammary epithelial cells were labeled by injecting the animals with BrdU 
(“Baseline”). Separate groups of vehicle- and TCDD-exposed animals were also administered a 
single dose of DMBA and sacrificed six days afterward (“DMBA”) (n=7 mice for each treatment 
group). BrdU positive cells in mammary gland slices were detected by immunohistochemistry. 
(C) Examples of tissue sections showing the BrdU stained cells (arrows) from vehicle- and 
TCDD-pretreated mice following DMBA exposure. Photos were taken at 400x. “D” indicates a 
duct, “Ad” indicates adipocytes.  (D) Quantification of the proliferating cells was conducted by 
counting the total number of BrdU stained cells in 10 separate images from each gland. 
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Figure 6: Effect of TCDD on CXCL12 and CXCR4 expression. Parous mice were treated 
with three weekly doses of vehicle or TCDD, as described in the Methods. CXCL12 and CXCR4 
expression were analyzed by qRT-PCR using RNA isolated from mammary glands of mice 
(n=5-6) sacrificed either 3 days (A), or 4 weeks (B), after the final TCDD treatment. (C) mRNA 
isolated from mammary tumors collected during the tumor study shown in Figure 3 (n=4) were 
also analyzed.  * p ≤ 0.05 and a fold-change of ≥ 2 relative to vehicle. [The decrease in CXCL12 
expression in (B) is technically statistically significant, but is substantially less than 2-fold. The p 
value for the decrease in CXCR4 expression in (C) is 0.07]. 
 
 
Supplementary Figure 1: TCDD treatment causes a transient reduction in AhR expression 
in the mammary gland. AhR levels were assessed in mammary gland protein extracts using 
Western blotting. Mice were treated with three weekly doses of vehicle or TCDD, as described 
in the Methods. Tissues were collected at two time points: three days (A), and four weeks (B), 
after the final vehicle or TCDD treatment. Two AhR bands are present because CB6F1 mice are 
heterozygous for AhRb-1 (95 kDa) and AhRb-2 (104 kDa). Actin (46 kDa) was used as a loading 
control. Bar graphs represent the average level of AhR normalized to actin (±SEM). Tissues 
from nulliparous mice were used in the three day timepoint, and parous mice were the source of 
tissues taken at 4 weeks.  * p ≤ 0.05. 
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